Skip to main
OFIX

Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix International (OFIX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Orthofix Medical Inc. demonstrates a robust financial trajectory, underscored by sustained growth in its global spine segment, which achieved an impressive 8% revenue growth in the U.S. during the quarter. The company's international orthopedics business showcases incremental progress with 1% growth, while the BGT fracture segment exhibits a solid 4% increase, implying a positive long-term market outlook bolstered by anticipated cross-selling opportunities. Additionally, notable gains in specific spinal product categories indicate strong market share capture, with lateral procedures and minimally invasive lumbar procedures growing by 24% and 18%, respectively, further enhancing the positive growth narrative for the company.

Bears say

Orthofix Medical Inc. exhibited a high GAAP SG&A expense of 72.0% of revenue, exceeding expectations of 66.7%, which reflects operational inefficiencies that may hinder profitability. Additionally, while adjusted EBITDA of $25.1 million surpassed projections, it raises concerns due to an overall lowered revenue forecast of approximately $820 million, reliant on M6 revenue contributions. These financial indicators suggest potential risks and inconsistencies in achieving future growth targets, prompting a cautious outlook on the company’s stock performance.

Orthofix International (OFIX) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orthofix International (OFIX) Forecast

Analysts have given Orthofix International (OFIX) a Buy based on their latest research and market trends.

According to 5 analysts, Orthofix International (OFIX) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orthofix International (OFIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.